ERBB2 and endometrial cancer: Furthermore, AZD8055, a dual mTORC1/2 inhibitor, demonstrated significant tumor growth inhibition in high HER-2/neu-expressor endometrial cancers in vitro (English, et al., 2013) as well as in vivo regression in breast, lung, colon, prostate, and uterine xenograft models (Chresta et al., 2010).